Zams

This research aims to evaluate the effectiveness of trastuzumab deruxtecan (T-DXd) in adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously been treated with a trastuzumab-based regimen. The study also collects patient demographic and clinical information, treatment patterns, and safety data including serious adverse events and drug reactions. It includes a disease registry for patients receiving conventional therapies in a real-world European setting. The study is non-interventional, meaning no investigational drugs are administered beyond standard care. Patients receiving T-DXd will be treated according to the Summary of Product Characteristics (SmPC), and data on conventional therapies such as platinum-fluoropyrimidine chemotherapy, nivolumab, ramucirumab-paclitaxel, taxane, irinotecan, and pembrolizumab will also be gathered. Treatment choices and administration follow the physician's decision and routine clinical practice. Participants will be monitored from baseline to about two years to assess the time to next treatment. Researchers will collect clinical data, treatment details, tolerability, and patient surveys to understand outcomes and safety. The study involves regular follow-up and data collection to track treatment effectiveness and patient experience in real-world settings.

Colorectal cancer (CRC) is a leading cause of cancer-related deaths in the United States and Europe. Most patients with metastatic colorectal cancer (mCRC) receive palliative care with a median overall survival of 9 to 38 months, depending on various factors. Promising treatment results have been seen in advanced stages, especially in patients receiving third-line therapy and beyond. This research aims to create a disease-specific registry to study treatment patterns and outcomes for mCRC patients who have undergone at least two prior systemic therapies. The registry collects retrospective and prospective data from multiple oncology centers in Austria. It includes patient medical records, testing, and treatment information, along with follow-up data on survival and tumor progression. Imaging studies at three or more lines of therapy are stored centrally in an "imaging-bank," and tumor tissue samples from deceased patients are preserved in a "bio-bank." Additional biomaterial, such as ctDNA or DNA from genotyping, may also be requested for specific research questions. No additional diagnostic or therapeutic interventions are required beyond routine care, and patient confidentiality is maintained through unique identifiers. Participants provide written consent before their data is included, except for deceased patients where no consent is needed. The registry does not interfere with usual treatment routines and only uses existing data from medical charts. Researchers will assess outcomes including overall survival, progression-free survival, response rates, and biomarker identification over a 10-year period. Data collection continues until patient death or loss to follow-up, with contributions from all willing sites.

Researchers are collecting and analyzing real-world data on treatment patterns, clinical outcomes, and side effects in adults with advanced pancreatic ductal adenocarcinoma (PDAC) in Austria. The study focuses on patients with locally advanced inoperable or metastatic PDAC who are receiving first-line chemotherapy. This research includes individuals undergoing palliative treatment to better understand how these treatments work in everyday clinical practice. Participants receive various approved chemotherapy drugs from the second line of treatment after progression on first-line therapies such as platinum- or gemcitabine-based chemotherapy or nal-Irinotecan/5-FU/Leukovorin when previously treated. The study plans to include 1500 adult patients and observes their treatment courses and outcomes over time, particularly focusing on those undergoing palliative second-line therapy. During the study, researchers will monitor treatment patterns, clinical results, and toxicities. The main outcome measured is the proportion of patients with locally advanced inoperable or metastatic PDAC receiving palliative second-line therapy after first-line chemotherapy progression, observed over 24 months. Patient information and treatment data will be collected prospectively or retrospectively, with consent obtained from prospective participants.

Researchers are evaluating the effects of Sonodyn, an investigational handheld medical device, on adults suffering from therapy-resistant myofascial pain syndrome causing low back pain, tension headache, or neck pain. This chronic pain condition affects muscles or muscle groups and is a common cause of musculoskeletal pain and dysfunction. The study is a randomized, sham-controlled, double-blind, multi-center trial conducted in Austria and Switzerland to compare active Sonodyn therapy with a non-functional sham device. The Sonodyn device combines low-energy ultrasound, electrical, and magnetic field stimulation for non-invasive treatment by placing it over specific pain trigger points. Participants are randomized in a 2:1 ratio to receive either the active device that delivers stimulation or the sham device that looks identical but emits no signals. After a 1-week screening phase, patients use their assigned device three times daily for 10 minutes each over a 3-week treatment period, followed by an 8-week follow-up. During the study, participants report their average and maximum pain intensity twice daily using a Numeric Rating Scale (NRS) and record any use of rescue medication. The primary outcome measure is the average NRS pain score after 3 weeks. Researchers will assess differences between the active therapy and sham groups, correlating pain intensity changes with other pain-related scales. Total participation lasts 12 weeks, including screening, treatment, and follow-up.